Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up
Keywords
Neuropathy, peripheral neuropa...
Neuropathy, peripheral neuropathy, pain management in neuropathy, pain management
#21
JOURNAL ARTICLE
Gabriel Marques, Alysson V Braga, Iara R Silva, Adna R B de Souza, Markus Kohlhoff, Isabela C César, Renes R Machado, Renata de Oliveira
Cannabidiol (CBD) is a substance that exerts several therapeutic actions, including analgesia. CBD is generally administered orally, but its poor water solubility and metabolism impairs its bioavailability. Thus, the development of molecules with better pharmacokinetic profile from cannabidiol becomes an interesting strategy for the design of novel analgesic drugs for the relief of painful conditions that are difficult to manage clinically, such as neuropathic pain. In the present study, an unprecedented analogue of CBD (1) was synthesized and some of its physicochemical properties were evaluated in silico as well as its stability in an acid medium...
February 16, 2024: Chemistry & Biodiversity
#22
JOURNAL ARTICLE
Fatma Ballı Uz, Cuma Uz, Ozgur Zeliha Karaahmet
BACKGROUND: Guillain-Barré syndrome (GBS), the most common cause of acute paralytic neuropathy, covers a number of recognizably different variants. We aimed to evaluate the clinical characteristics of the patients with GBS and the outcome results of the patients after rehabilitation. METHODS: We enrolled 24 adult patients with GBS and evaluated their demographic characteristics, signs, complications, functional levels, and residual symptoms at admission, discharge, and during the 1st and 3rd-year follow-up visits...
September 2023: Malawi Medical Journal: the Journal of Medical Association of Malawi
#23
JOURNAL ARTICLE
Haekyu Kim, Hyae Jin Kim, Young-Hoon Jung, Wangseok Do, Eun-Jung Kim
BACKGROUND: Among the various pain-related diseases that can be encountered at the clinic, there is a neuropathic pain that is difficult to treat. Numerous methods have been proposed to treat neuropathic pain, such as taking medication, nerve block with lidocaine, or neurolysis with alcohol or phenol. Recently, a method of perineural injection using dextrose instead of lidocaine was proposed. This study was designed to compare the effects of perineural injection therapy (PIT) with buffered 5% dextrose or 0...
February 2024: Journal of Dental Anesthesia and Pain Medicine
#24
JOURNAL ARTICLE
María Fernanda Pérez Hernández, Alejandra Calderón Vallejo, Sergio de Jesús Aguilar Castillo, Daniel Cuauhtémoc Gómez Jiménez, Eduardo Rodríguez Guerrero, Fátima Aguilar Morales, Macedonia Guadalupe Moreno Tovar, Miguel Alfredo Zurita Muñóz, Antonio Eduardo Bautista Cortéz, Claudia Camelia Calzada Mendoza, Mónica Ascención De Nova Ocampo, Juan Manuel Ordóñez Rodríguez, Mónica Luz Gómez Esquivel, Alberto García Méndez, Octavio Flores Gil, Víctor Manuel Macías Zaragoza, Gabriela Yanet Cortés Moreno, Citlaltepetl Salinas Lara, Germán Velázquez García, Héctor Iván Saldivar Cerón, Lucia Monserrat Pérez Navarro, Laura Ávila Jiménez, Jaime Héctor Gómez Zamudio, Margarita Díaz Flores, Miguel Cruz López, María Esther Ocharan Hernández, José de Jesús Peralta Romero
BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common complication of type 2 diabetes mellitus (T2DM); its diagnosis and treatment are based on symptomatic improvement. However, as pharmacological therapy causes multiple adverse effects, the implementation of acupunctural techniques, such as electroacupuncture (EA) has been suggested as an alternative treatment. Nonetheless, there is a lack of scientific evidence, and its mechanisms are still unclear. We present the design and methodology of a new clinical randomized trial, that investigates the effectiveness of EA for the treatment of DPN...
February 15, 2024: BMC complementary medicine and therapies
#25
JOURNAL ARTICLE
Ruth Sindie, Elias Mwakilama, Pachalo Chizala, Jimmy Namangale
AIDS is an incurable disease that is common in Africa. Patients with HIV/AIDS having a CD4 count of less than 240 are put on life prolonging ARV drugs. The ARVs have serious side effects on some patients which may be handled by treating them or switching patient's drug to one with no or less serious side effects. However, before doing this, more understanding of the circumstances that lead to a side effect is vital. We use statistical analyses to link side effects of 1A, 2A, and 5A treatment regimens to the patient's social and demographic characteristics based on hospital data records...
September 2023: African Health Sciences
#26
JOURNAL ARTICLE
Natsuki Nakagawa, Sena Yamamoto, Akiko Hanai, Ayano Oiwa, Harue Arao
PURPOSE: Although exercise is recommended for cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN), the effective types of exercise for preventing and treating CIPN remain unclear. This systematic review and network meta-analysis (NMA) aimed to evaluate the comparative effects of exercise on CIPN. METHODS: We included relevant randomized controlled trials (RCTs) identified in a 2019 systematic review that evaluated the effects of exercise on CIPN and conducted an additional search for RCTs published until 2023...
2024: Frontiers in Neurology
#27
JOURNAL ARTICLE
G Arun Maiya, Radhika Aditya Jadhav, Hrishikesh Yadav K, Manjunatha Hande H, Harishchandra Hebbar, Karthik Mohan
BACKGROUND: Photobiomodulation (PBM) or Low-level laser is used to treat diabetic foot complications. The existing method of laser application to the foot did not cover the foot's entire area to improve the foot's microcirculation. Therefore, we have developed a cost-effective Special LASER Shoe device, focusing exclusively on the entire foot region to manage neuropathic pain and other symptoms in individuals with type 2 diabetes mellitus. OBJECTIVE: The main objective of the present study was to evaluate the effect of this newly developed special laser shoe PBM on neuropathic pain and plantar pressure profile in individuals with type 2 diabetes mellitus with neuropathy...
February 13, 2024: Current Diabetes Reviews
#28
JOURNAL ARTICLE
Inaeh de Paula Oliveira, Victória Regina da Silva Oliveira, Heloísa Alonso-Matielo, Beatriz Magalhães Eng, Daniel Ciampi de Andrade, Manoel Jacobsen Teixeira, Milena Cristina Dias Calsaverini, Fernando de Quadros Ribeiro, José Deney Alves Araújo, Helder Takashi Imoto Nakaya, José Pinhata Otoch, Camila Squarzoni Dale
BACKGROUD: Diabetic neuropathy (DN) is one of the most common complications of diabetes, affecting about half of individuals with the disease. Among the various symptoms of DN, the development of chronic pain stands out and manifests as exacerbated responses to sensorial stimuli. The conventional clinical treatments used for general neuropathy and associated painful symptoms, still brings uncomplete and unsatisfactory pain relief. Patients with neuropathic pain syndromes are heterogeneous...
February 13, 2024: Pain Practice: the Official Journal of World Institute of Pain
#29
REVIEW
Gabriela Becker, Samuel Felipe Atuati, Sara Marchesan Oliveira
Cisplatin is a platinum-based chemotherapy drug widely used to treat various solid tumours. Although it is effective in anti-cancer therapy, many patients develop peripheral neuropathy during and after cisplatin treatment. Peripheral neuropathy results from lesions or diseases in the peripheral somatosensory nervous system and is a significant cause of debilitation and suffering in patients. In recent years, preclinical studies have been conducted to elucidate the mechanisms involved in chemotherapy-induced peripheral neuropathic pain, as well as to promote new therapeutic targets since current treatments are ineffective and are associated with adverse effects...
January 30, 2024: Cancers
#30
Sankalp Yadav
Tuberculosis is prevalent in high-burden countries. Extrapulmonary drug-resistant tuberculosis is exceedingly rare. Simultaneous involvement of the spine with psoas muscles in the absence of pulmonary seeding with a drug-resistant strain of Mycobacterium tuberculosis in an adult female is never reported. A 33-year-old Indian female presented with complaints of chronic back pain for eight months. She was on antituberculous treatment for Pott's spine for six months. The diagnosis was challenging due to the paucibacillary nature of the disease, and it required a high index of suspicion backed by radiometric investigations, liquid culture, a line probe assay, and cartridge-based nucleic acid amplification of the pus...
January 2024: Curēus
#31
JOURNAL ARTICLE
Barbara H Braffett, Laure El Ghormli, James W Albers, Eva L Feldman, William H Herman, Rose A Gubitosi-Klug, Catherine L Martin, Trevor J Orchard, Neil H White, John M Lachin, Bruce A Perkins, Rodica Pop-Busui
OBJECTIVE: Diabetic peripheral neuropathy (DPN) is common; however, the features and burden of neuropathic pain (NP) in type 1 diabetes (T1D) are poorly understood. We evaluated the incidence of first occurrence, annual prevalence, remission, and risk factors for NP during long-term follow-up of participants with T1D. RESEARCH DESIGN AND METHODS: The Michigan Neuropathy Screening Instrument (MNSI) was administered annually (1994-2020) for 1,324 participants in the Epidemiology of Diabetes Interventions and Complications (EDIC) study...
February 1, 2024: Diabetes Care
#32
Aakaash Venkatesan, Chandan Noel, Waleed Akeel
INTRODUCTION: Diabetic foot attack (DFA), also known as diabetic foot ulceration, is a severe and potentially limb-threatening complication of diabetes mellitus. It refers to the development of open sores or ulcers on the feet of individuals with diabetes, often leading to infections, tissue damage, and, in extreme cases, amputation. The underlying cause of DFAs is multifactorial and involves a complex interplay of various factors, including peripheral neuropathy, peripheral arterial disease, foot deformities, impaired wound healing, and poor glycemic control...
January 2024: Journal of Orthopaedic Case Reports
#33
JOURNAL ARTICLE
You-Wun Jheng, Ya-Ning Chan, Chih-Jung Wu, Ming-Wei Lin, Ling-Ming Tseng, Ya-Jung Wang
BACKGROUND: Despite the significant impact of chemotherapy-induced peripheral neuropathy on the quality of life for breast cancer survivors, there is a notable lack of comprehensive research. Therefore, a crucial need exists for further systematic investigation and inquiry into this matter. AIMS: This study examined predictors of quality of life in breast cancer survivors with chemotherapy-induced peripheral neuropathy. DESIGN: A cross-sectional, correlational design...
January 25, 2024: Pain Management Nursing: Official Journal of the American Society of Pain Management Nurses
#34
JOURNAL ARTICLE
Huanbai Wang, Xiaodan Li, Yamin Qiao, Meiting Wang, Wen Wang, J Michael McIntosh, Dongting Zhangsun, Sulan Luo
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting painful neuropathy that occurs commonly during cancer management, which often leads to the discontinuation of medication. Previous studies suggest that the α9α10 nicotinic acetylcholine receptor (nAChR)-specific antagonist αO-conotoxin GeXIVA[1,2] is effective in CIPN models; however, the related mechanisms remain unclear. Here, we analyzed the preventive effect of GeXIVA[1,2] on neuropathic pain in the long-term oxaliplatin injection-induced CIPN model...
January 19, 2024: Marine Drugs
#35
JOURNAL ARTICLE
Mohamad Mroué, Flavien Bessaguet, Angélique Nizou, Laurence Richard, Franck Sturtz, Laurent Magy, Sylvie Bourthoumieu, Aurore Danigo, Claire Demiot
The occurrence of neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting effect of many commonly-used anticancer agents. Polyvalent human immunoglobulins (hIg), used in the treatment of several peripheral neuropathies, may alleviate neuropathic pain. The aim of this project was to investigate the preventive effect of hIg in two mouse models of CIPN, induced by vincristine (VCR, 100 µg/kg/d) and oxaliplatin (OXP, 6 mg/kg/3d). Human Ig were administered one day before the first injection of chemotherapy...
January 20, 2024: Pharmaceutics
#36
JOURNAL ARTICLE
Dan Ziegler
Diabetic peripheral neuropathy (DPN) is found in around one third of people with diabetes, but remains inadequately diagnosed and treated. Its management includes three cornerstones: 1) causal treatment with lifestyle modification, intensive diabetes therapy aimed at near-normoglycemia, and multifactorial cardiovascular risk intervention, 2) pathogenesis-oriented pharmacotherapy, and 3) symptomatic pain relief. Since symptomatic analgesic monotherapy only relieves the pain without targeting the underlying neuropathy and both has limited efficacy and is associated with adverse events, there is an unmet need for additional approaches derived from the pathogenetic concepts of DPN...
December 2023: Diabetes Research and Clinical Practice
#37
JOURNAL ARTICLE
A J M Boulton, T S Jensen, T Luecke, E A Petersen, R Pop-Busui, R S Taylor, S Tesfaye, L Vileikyte, D Ziegler
BACKGROUND: Although pharmacotherapy with anticonvulsants and/or antidepressants can be effective for many people with painful diabetic neuropathy (PDN), albeit with frequent side-effects, a critical juncture occurs when neuropathic pain no longer responds to standard first- and second-step mono- and dual therapy and becomes refractory. Subsequent to these pharmacotherapeutic approaches, third-line treatment options for PDN may include opioids (short-term), capsaicin 8% patches, and spinal cord stimulation (SCS)...
December 2023: Diabetes Research and Clinical Practice
#38
JOURNAL ARTICLE
Solomon Tesfaye, Peter Kempler
Painful Diabetic Peripheral Neuropathy (PDN) is common, affecting around a quarter of patients with both type 1 and type 2 diabetes, and can lead to significant curtailment of functionality and quality of life. Patients may present with unremitting burning, aching or "electric-shock" type pains in their feet, legs and later, in the hands. Conventional management approaches must focus not only on pain relief, but also on concurrent sleep problems, mood disorders and functionality. The mainstay of treatment is pharmacotherapy...
December 2023: Diabetes Research and Clinical Practice
#39
JOURNAL ARTICLE
Alice L Ye, Emily W Sudek, Daniela Magdaleno, Carlos J Roldan
Aim: Micronutrient and metabolic compound supplementation as a method of treating chronic pain is not well understood. Case: A 58 year-old woman presented with refractory painful neuropathy. She did not respond to conservative treatment and was seeking spinal cord stimulator implantation. She underwent a biomarker panel that revealed low intracellular levels of multiple compounds. As she supplemented her deficiencies, her symptoms fully resolved, and the implant was no longer indicated. Discussion: Micronutrient and metabolic compound testing could potentially expand non-invasive treatment options for patients with refractory chronic pain...
January 9, 2024: Pain Management
#40
Janus Patel, Emily Deschler, Enrique Galang
BACKGROUND: Stiff person syndrome (SPS) is a rare neuroimmunological disorder characterized by rigidity and painful spasm primarily affecting the truncal and paraspinal musculature due to autoimmune-mediated neuronal hyperexcitability. Spinal cord stimulation (SCS) is an approved therapy for managing painful neuropathic conditions, including diabetic peripheral neuropathy and refractory angina pectoris. We describe the novel use of SCS for the treatment of spasm and rigidity in a 49-year-old man with seropositive stiff person syndrome (SPS)...
January 7, 2024: Pain Practice: the Official Journal of World Institute of Pain
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
